The study of antitumor activity in vitro and in vivo of TRAIL-Fc
LUO Lan,LIU Hong-hong,LI Xiang,FAN Kai
DOI: https://doi.org/10.3969/cmba.j.issn.1673-713X.2011.01.005
2011-01-01
Abstract:Objective To study the antitumor activity in vitro and in vivo of TRAIL-Fc recombinant fusion protein with the Fc fragment of human antibody.Methods ①The experiment in vitro:human acute T lymphoblastic leukemia Jurkat cells,human colon cancer LOVO cells,human gastric cancer MKN45 cells,human epidermal carcinoma A431 cells,human hepatic carcinoma HEPG2 cells,human breast cancer MCF-7 cells,mice hepatic carcinoma H22 cells were divided into TRAIL-Fc recombinant fusion protein group,control group and blank control group randomly,and treated with 1000、250、62.5、15.6、3.9、0.97 ng/ml TRAIL-Fc recombinant fusion protein,TRAIL reference substance and complete medium respectively.The growth inhibition rates of 7 kinds of tumor cell lines affected by TRAIL-Fc recombinant fusion protein were detected by MTT method.②The experiment in vivo:H22 cells were injected into abdominal and armpit of mice to establish liver cancer model,according to the different drugs,the mice were divided into blank control group,5-Fu group and TRAIL-Fc recombinant fusion protein group randomly.And the abdominal circumference and body weight of mice injected H22 celles into abdominal and tumor volume of mice injected H22 celles into armpit were measured.The mice were killed after collecting peripheral blood at day 15,calculating the tumor inhibition rate,and detecting the AST,ALT levels in mice serum.Results The results of experiment in vitro showed that TRAIL-Fc recombinant fusion protein could inhibit the growth of 7 kinds of tumor cell lines in dose-dependent manners,and the inhibition to MCF-7 cells was the strongest,the growth inhibition rates was 82.5%,and LOVO cells(81.9%),MKN45 cells(52.3%),H22 cells(51.2%),Jurkat cells(50.9%),HEPG2 cells(35.4%),A431 cells(20.3%) were followed.Compared with the reference substance,the TRAIL-Fc recombinant fusion protein to LOVO cells(IC50 83.5),MKN45 cells(IC50 243.2) and MCF-7 cells(IC50 84.6) had more sensitivity.The results of experiment in vivo showed that in the blank control group,the mice abdomen swelled obviously,body weight decreased slightly late,and tumor volume continued to increase;in the TRAIL-Fc recombinant fusion protein group,the mice abdomen swelled slightly,body weight remained stable,and tumor volume increased slightly late;in the 5-Fu group,the mice had no abdominal swelling,body weight drop sharply,and tumor volume reduced significantly.The tumor inhibition rate of TRAIL-Fc recombinant fusion protein was 45.79%,and the results of AST,ALT showed that it had no effect on mice liver function.Conclusion The TRAIL-Fc recombinant fusion protein had strong ability to inhibit tumor cells growth and significantly longer half-life in vivo.